Gastrointestinal neuroendocrine tumors (Q37799954)

23 August 2017

Gastrointestinal neuroendocrine tumors (English)

1 reference

23 August 2017

K E Öberg

1

1 reference

23 August 2017

1 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

21 Suppl 7

1 reference

23 August 2017

vii72-80

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

23 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Neuroendocrine tumor epidemiology: contrasting Norway and North America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Updated population-based review of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Carcinoid--a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Well-differentiated pancreatic nonfunctioning tumors/carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Standardisation of imaging in neuroendocrine tumours: results of a European delphi process

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

The diagnosis and medical management of advanced neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Biology and management of the midgut carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Therapeutic options for gastrointestinal carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Rationale for the use of somatostatin analogs as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Pasireotide (SOM230): development, mechanism of action and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Pharmacodynamic effects of Sandostatin in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Neuroendocrine tumors. Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

21 January 2018

Somatostatin receptors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ290

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ290

1 reference

23 August 2017

1 reference

PubMed ID

20943646